Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-SiglecF antibody is a monoclonal antibody directed against Siglec-F, a sialic acid-binding immunoglobulin-like lectin primarily expressed on mouse eosinophils. The antibody works by engaging and cross-linking Siglec-F on eosinophils, leading to induction of apoptosis and depletion of eosinophils in vivo and in vitro. Siglec-F is the closest functional paralog of human Siglec-8, which is also a target for anti-eosinophil therapies. Studies in mice demonstrate that administration of anti-SiglecF antibody results in a rapid and significant decrease in blood and tissue eosinophils via selective induction of eosinophil cell death, supporting potential therapeutic applications in mouse models of eosinophil-associated diseases. This antibody is primarily a research and preclinical tool in murine disease models, not a clinical drug for humans[1][12].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-siglecf antibody.